FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952905145> ?p ?o ?g. }

• W2952905145 abstract "To assess the risks of malignancies, infections and autoimmune diseases in patients with rheumatoid arthritis (RA) treated with abatacept compared with other biologic (b) disease-modifying antirheumatic drugs (DMARDs) or conventional synthetic (cs)DMARDs, in a US-wide observational RA cohort Data were reviewed from patients (≥ 18 years) with RA who were registered with FORWARD, the National Databank for Rheumatic Diseases, and who initiated abatacept, other bDMARDs or csDMARDs between 2005 and 2015. Patients who switched treatment during the study could be allocated to more than one group. The incidence rates (IRs) by treatment were calculated for malignancies, hospitalized infections and autoimmune diseases identified by six monthly questionnaires and medical records. The hazard ratios (HRs) (95% confidence intervals [CIs]) for all outcomes with abatacept compared with other bDMARDs or csDMARDs were determined using marginal structural models adjusted for clinical confounders. In the study sample, 1496 initiated abatacept, 3490 initiated another bDMARD and 1520 initiated a csDMARD. The risk of malignancies with abatacept was not statistically significant versus other bDMARDs (HR [95% CI)] 1.89 [0.93, 3.84]) or versus csDMARDs (HR [95% CI] 0.93 [0.20, 4.27]). Patients receiving abatacept versus other bDMARDs were at a lower risk of hospitalized infections (HR [95% CI] 0.37 [0.18, 0.75]); the risk versus csDMARDs was lower with wide CIs (HR [95% CI] 0.31 [0.09, 1.05]). The relative risks for psoriasis were similar between treatment groups (HR [95% CI] 1.46 [0.76, 2.81] and HR [95% CI] 2.05 [0.59, 7.16] for abatacept versus other bDMARDs and versus csDMARDS, respectively). The IR (95% CI) of severe infusion/injection reactions was lower with abatacept compared with other bDMARDs (1.57 [1.11, 2.17] vs 2.31 [1.87, 2.82] per 100 patient-years, respectively). In this analysis, abatacept was well tolerated and did not result in an overall increased risk of malignancies, infections or autoimmune diseases compared with other bDMARDs or csDMARDs." @default.
• W2952905145 created "2019-06-27" @default.
• W2952905145 creator A5005535362 @default.
• W2952905145 creator A5013888254 @default.
• W2952905145 creator A5041110185 @default.
• W2952905145 creator A5044067217 @default.
• W2952905145 creator A5086239129 @default.
• W2952905145 date "2019-06-07" @default.
• W2952905145 modified "2023-10-06" @default.
• W2952905145 title "Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study" @default.
• W2952905145 cites W1485393587 @default.
• W2952905145 cites W1784492827 @default.
• W2952905145 cites W1849140529 @default.
• W2952905145 cites W1984049620 @default.
• W2952905145 cites W2009187570 @default.
• W2952905145 cites W2009298607 @default.
• W2952905145 cites W2014081699 @default.
• W2952905145 cites W2023380965 @default.
• W2952905145 cites W2028514817 @default.
• W2952905145 cites W2039207296 @default.
• W2952905145 cites W2060549798 @default.
• W2952905145 cites W2074396393 @default.
• W2952905145 cites W2078744808 @default.
• W2952905145 cites W2079359234 @default.
• W2952905145 cites W2097145477 @default.
• W2952905145 cites W2097341637 @default.
• W2952905145 cites W2100974168 @default.
• W2952905145 cites W2113375444 @default.
• W2952905145 cites W2113609304 @default.
• W2952905145 cites W2115018403 @default.
• W2952905145 cites W2117335168 @default.
• W2952905145 cites W2122018306 @default.
• W2952905145 cites W2124670599 @default.
• W2952905145 cites W2133089226 @default.
• W2952905145 cites W2148203266 @default.
• W2952905145 cites W2148666195 @default.
• W2952905145 cites W2152350812 @default.
• W2952905145 cites W2171422552 @default.
• W2952905145 cites W2187573191 @default.
• W2952905145 cites W2284636686 @default.
• W2952905145 cites W2527726258 @default.
• W2952905145 cites W2535171500 @default.
• W2952905145 cites W2537052214 @default.
• W2952905145 cites W2549517006 @default.
• W2952905145 cites W2561358587 @default.
• W2952905145 cites W2591234938 @default.
• W2952905145 cites W2621822310 @default.
• W2952905145 cites W2755252346 @default.
• W2952905145 cites W2762986374 @default.
• W2952905145 cites W2766244499 @default.
• W2952905145 cites W2914132499 @default.
• W2952905145 cites W2917800966 @default.
• W2952905145 cites W4236700223 @default.
• W2952905145 doi "https://doi.org/10.1186/s13075-019-1921-z" @default.
• W2952905145 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6555014" @default.
• W2952905145 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31174592" @default.
• W2952905145 hasPublicationYear "2019" @default.
• W2952905145 type Work @default.
• W2952905145 sameAs 2952905145 @default.
• W2952905145 citedByCount "36" @default.
• W2952905145 countsByYear W29529051452019 @default.
• W2952905145 countsByYear W29529051452020 @default.
• W2952905145 countsByYear W29529051452021 @default.
• W2952905145 countsByYear W29529051452022 @default.
• W2952905145 countsByYear W29529051452023 @default.
• W2952905145 crossrefType "journal-article" @default.
• W2952905145 hasAuthorship W2952905145A5005535362 @default.
• W2952905145 hasAuthorship W2952905145A5013888254 @default.
• W2952905145 hasAuthorship W2952905145A5041110185 @default.
• W2952905145 hasAuthorship W2952905145A5044067217 @default.
• W2952905145 hasAuthorship W2952905145A5086239129 @default.
• W2952905145 hasBestOaLocation W29529051451 @default.
• W2952905145 hasConcept C126322002 @default.
• W2952905145 hasConcept C198451711 @default.
• W2952905145 hasConcept C207103383 @default.
• W2952905145 hasConcept C23131810 @default.
• W2952905145 hasConcept C2777226972 @default.
• W2952905145 hasConcept C2777575956 @default.
• W2952905145 hasConcept C2778886723 @default.
• W2952905145 hasConcept C2779338263 @default.
• W2952905145 hasConcept C2779605438 @default.
• W2952905145 hasConcept C2780653079 @default.
• W2952905145 hasConcept C44249647 @default.
• W2952905145 hasConcept C71924100 @default.
• W2952905145 hasConceptScore W2952905145C126322002 @default.
• W2952905145 hasConceptScore W2952905145C198451711 @default.
• W2952905145 hasConceptScore W2952905145C207103383 @default.
• W2952905145 hasConceptScore W2952905145C23131810 @default.
• W2952905145 hasConceptScore W2952905145C2777226972 @default.
• W2952905145 hasConceptScore W2952905145C2777575956 @default.
• W2952905145 hasConceptScore W2952905145C2778886723 @default.
• W2952905145 hasConceptScore W2952905145C2779338263 @default.
• W2952905145 hasConceptScore W2952905145C2779605438 @default.
• W2952905145 hasConceptScore W2952905145C2780653079 @default.
• W2952905145 hasConceptScore W2952905145C44249647 @default.
• W2952905145 hasConceptScore W2952905145C71924100 @default.
• W2952905145 hasFunder F4320307115 @default.
• W2952905145 hasIssue "1" @default.
• W2952905145 hasLocation W29529051451 @default.
• W2952905145 hasLocation W29529051452 @default.

• next